8-K: Centessa Pharmaceuticals Secures FDA Clearance for ORX142, Advancing Orexin Agonist Pipeline into Phase 1 Clinical Study

Centessa Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ORX142, a novel orexin receptor 2 (OX2R) agonist, enabling the initiation of a Phase 1 clinical study.

Summary

• Centessa Pharmaceuticals plc received U.S. FDA clearance for its Investigational New Drug (IND) application for ORX142.
• ORX142 is a novel, highly potent, and selective Orexin Receptor 2 (OX2R) agonist intended for select neurological and neurodegenerative disorders.
• This marks ORX142 as the second drug candidate from Centessa's multi-asset orexin franchise.
• The company plans to initiate the first-in-human Phase 1 clinical study of ORX142 imminently in healthy volunteers.
• The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of ORX142.
• A placebo-controlled crossover pharmacodynamic (PD) assessment using the Maintenance of Wakefulness Test (MWT) and Karolinska Sleepiness Scale (KSS) will be performed in acutely sleep-deprived healthy adult subjects.
• Clinical data from the ORX142 Phase 1 study is expected this year, aiming to generate early proof-of-concept data for dose selection in future patient studies.
• Centessa's most advanced OX2R agonist, ORX750, is currently advancing in the Phase 2a CRYSTAL-1 study for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).
• The company is also developing ORX489 for neuropsychiatric disorders as part of its OX2R agonist pipeline.
• Centessa also has an early-stage immuno-oncology program focused on its novel LockBody technology platform.

Sentiment

Score: 8

Explanation: The document announces a significant positive regulatory milestone (FDA IND clearance) for a new drug candidate, enabling the start of human clinical trials. This is a key de-risking event in pharmaceutical development and expands the company's pipeline potential. While no financial metrics are provided, the clinical progress is a strong positive.

Positives

• FDA clearance of the IND for ORX142 is a significant regulatory milestone, allowing clinical studies to commence.
• ORX142 is a novel, highly potent, and selective OX2R agonist, representing a promising therapeutic approach.
• The clearance expands Centessa's orexin franchise beyond rare hypersomnias, exploring potential for a broad range of neurological and neurodegenerative disorders.
• Early proof-of-concept data for ORX142 is expected this year, which could enable dose selection for future patient studies.
• The company's lead OX2R agonist, ORX750, is already advancing in a Phase 2a study for multiple sleep-wake disorders.

Risks

• Risks related to the safety and tolerability profile of product candidates.
• Ability to identify, screen, recruit, and maintain a sufficient number of subjects in existing and anticipated studies or clinical trials within anticipated timelines.
• Uncertainties regarding the predicted timing of enrollment and efficacious doses for ORX750 and ORX142.
• Ability to successfully conduct clinical development of ORX750 and ORX142.
• Ability to protect and maintain intellectual property position.
• Business, regulatory, economic, and competitive risks, uncertainties, contingencies, and assumptions.
• Risks inherent in developing product candidates and technologies.
• Uncertainty of future results from ongoing and planned clinical trials.
• Ability to obtain adequate financing, including through its financing facility with Oxford Finance, to fund planned clinical trials and other expenses.
• Trends in the industry and the legal and regulatory framework.
• Receipt and maintenance of clearances to conduct or continue clinical testing.
• Operating costs and use of cash, including cash runway, cost of development activities, and conducting clinical trials.
• Risk that any one or more product candidates will not be successfully developed and/or commercialized.
• Risk that historical results of preclinical or clinical studies will not be predictive of future results.
• Economic risks to the United States and United Kingdom banking systems.
• Geo-political risks such as the Russia-Ukraine war or the Middle East conflicts.

Future Outlook

Centessa Pharmaceuticals plans to initiate the Phase 1 clinical study of ORX142 imminently, with early proof-of-concept clinical data expected this year. This data is anticipated to enable dose selection for planned studies evaluating ORX142 in patients. The company continues to advance ORX750 in its Phase 2a CRYSTAL-1 study.

Management Comments

• Saurabh Saha MD PhD, Chief Executive Officer of Centessa, stated: 'The clearance of our IND to initiate clinical studies of ORX142 represents a significant milestone, signaling the beginning of an exciting new phase in the clinical development of our OX2R agonist pipeline for indications beyond rare hypersomnias.'
• Saurabh Saha MD PhD also commented: 'We are eager to leverage our insights from this new drug class and explore ORX142’s potential to treat a broad range of neurological and neurodegenerative disorders with significant unmet needs. We are excited to begin executing our ORX142 Phase 1 clinical study in acutely sleep-deprived healthy volunteers which is aimed at generating early proof-of-concept data for ORX142 this year which we expect to enable a dose selection for planned studies evaluating ORX142 in patients.'

Industry Context

Centessa Pharmaceuticals is focused on targeting the orexin pathway with novel orexin receptor 2 (OX2R) agonists, a promising approach for addressing excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue across various neurological, neurodegenerative, and neuropsychiatric disorders. This IND clearance for ORX142 further solidifies their position in this therapeutic area, complementing their lead candidate ORX750 and expanding their pipeline's potential reach.

Stakeholder Impact

• Shareholders: Positive impact due to pipeline progression, de-risking of a new drug candidate, and expansion of potential market opportunities.
• Patients: Potential for new treatment options for a broad range of neurological and neurodegenerative disorders with significant unmet needs.
• Employees: Continued progress in clinical development may provide stability and opportunities within the company.

Next Steps

• Initiate the first-in-human Phase 1 clinical study of ORX142 imminently.
• Generate early proof-of-concept clinical data for ORX142 this year.
• Conduct dose selection for planned studies evaluating ORX142 in patients.
• Continue advancing ORX750 in the Phase 2a CRYSTAL-1 study.

Key Dates

Keywords

Centessa Pharmaceuticals, ORX142, ORX750, FDA, IND clearance, Phase 1 clinical study, Orexin Receptor 2 agonist, OX2R agonist, Neurological disorders, Neurodegenerative disorders, Sleep-wake disorders, Narcolepsy, Idiopathic Hypersomnia, Clinical-stage pharmaceutical, Drug development